What Is a GLP-3 Pen? A Simple UAE Guide for Beginners

Beginner guide · Updated 29 July 2026 · UAE research education

07Interactive beginner guide

Key facts before you read further

Choose a familiar term, then open the cards that answer the most common questions.

Tap a term to decode itThe selected explanation changes below.

GLP-1SemaglutideMounjaroRetatrutide“GLP-3”

Natural biologyGLP-1 is a naturally occurring peptide hormone and receptor pathway.

Receptor scope

GLP-1 receptor

Evidence category

Established biology; each named medicine has separate evidence

Do not assume

GLP-1 is one universal product or pen

0 of 7 key facts explored

Different terms. Different meanings.01 · TerminologyDifferent names ≠ the same thingGLP-1, named medicines and “GLP-3” describe different concepts.+

Separate the natural hormone and pathway, a medicine class, a named medicine, an investigational candidate and a catalogue label before comparing evidence.

GLP-1≠Mounjaro≠Retatrutide≠“GLP-3”

Pen format ≠ identity or evidence02 · PresentationA pen is only a formatThe device shape cannot identify the evidence behind its contents.+

A pen can describe presentation and packaging. It does not, by appearance alone, establish molecular identity, approval, clinical effects, purity, sterility or intended use.

Pen formatdoes not proveIdentity or evidence

Named material → defined study → bounded finding03 · EvidenceEvidence follows the exact moleculeBenefits cannot jump from one medicine or study to another product.+

Appetite, blood-glucose, body-weight or other outcomes must remain attached to the exact named molecule, study population, protocol and jurisdiction.

Named molecule→Defined study→Bounded finding

Study measurement points ≠ your timeline04 · Study timingStudy length ≠ a personal timelineA measurement at week 48 or 72 is a research endpoint—not a promise.+

Trials use different populations, endpoints and measurement dates. A group average at a particular week cannot predict an individual result or another product’s behaviour.

Week 48
Study measurement≠Your timeline
Cannot be predicted here

Three clocks. Three different questions.05 · Three clocksTiming terms measure different thingsHalf-life, labelled schedule and study duration are not interchangeable.+

Half-lifeHow the amount of an exact molecule declines over timeLabelled scheduleWhat an exact approved product label specifiesStudy durationHow long researchers collected study data

Research catalogue ≠ personal treatment06 · Research statusThe Emirates pen is research-onlyIt is not presented as a prescribed diabetes or weight-management medicine.+

The Emirates Peptides GLP-3 Research Pen is a laboratory catalogue presentation. It is not for human or veterinary use and does not carry a treatment indication.

Check current research-pen availability →

Verify the exact product and current UAE information07 · UAE contextCheck the exact named product and current local statusApproval cannot be inferred from a familiar name, international article or pen shape.+

For Dubai, Abu Dhabi and the wider UAE, regulatory status must be checked against the current UAE authority and the exact local product information. This guide does not confirm UAE approval for any medicine.

Exact moleculeExact brandCurrent jurisdictionCurrent local label

03 · Beginner guide

Five terms that are easy to confuse

Use the surrounding explanation and cited source for the full context.

People often use “GLP” as if it were one product. It is better to separate the pathway, the medicine class, the named medicines and the research label.

This distinction is not a technicality. It prevents a result from one medicine or clinical candidate being copied onto a different product simply because both are supplied in pen-shaped devices.

04 · Beginner guide

What does GLP-1 do in the body?

Use the surrounding explanation and cited source for the full context.

GLP-1 stands for glucagon-like peptide-1. It is a hormone released from the gut after eating. It forms part of the body’s communication system between the digestive tract, pancreas and brain.

Four ideas help explain why the pathway receives so much attention:

Brain and fullness

GLP-1 signalling reaches areas involved in appetite and food intake. This is one reason named GLP-1 medicines have been studied for body-weight management. It does not mean that every product using “GLP” in its name has a proven effect on appetite.

Stomach and digestion

GLP-1 receptor activation can slow gastric emptying, especially early in treatment with some named medicines. Gastric emptying describes how quickly food leaves the stomach. The degree and duration of this effect can differ between products and over time.

Pancreas and insulin

GLP-1 can support insulin secretion when blood glucose is elevated. The phrase “glucose-dependent” matters: the pathway’s behaviour depends partly on the glucose environment rather than acting like a simple on/off insulin switch.

Glucagon signalling

GLP-1 activity can also affect glucagon, a hormone involved in maintaining blood glucose. Glucagon is not simply “bad.” It has normal physiological roles, and this becomes particularly relevant when researchers study molecules that deliberately include glucagon-receptor activity.

These are general pathway concepts. They explain why GLP-1 biology is scientifically and medically important, but they do not establish the identity or clinical effect of an unidentified research material.

05 · Beginner guide

Why are these products often supplied as pens?

A pen can make a product look familiar because approved medicines such as some semaglutide and tirzepatide presentations also use pen devices. But the shape of the container does not determine what the product is.

A pen may combine a cartridge, protective body and external label. This can make the item easier to identify, inventory and visually inspect. It does not answer the questions that matter most:

• What is the exact molecule?
• Does the batch match its documentation?
• What does the purity result actually measure?
• Has concentration been independently verified?
• Is there evidence for stability, sterility or biological activity?
• What regulatory status applies to this exact product?

Two pens can look similar while containing different substances. Start with the exact product name and documentation, not the device shape.

06 · Beginner guide

Single, dual and triple receptor scope

Use the surrounding explanation and cited source for the full context.

A receptor is a structure that receives a biological signal. An agonist is a molecule that activates a receptor. The terms single, dual and triple describe how many receptor pathways a named molecule is designed to engage.

Single-receptor example: semaglutide is a GLP-1 receptor agonist.

Dual-receptor example: tirzepatide activates GIP and GLP-1 receptors.

Triple-receptor example: retatrutide is designed to activate GIP, GLP-1 and glucagon receptors.

“Triple” does not automatically mean stronger, better or safer. A molecule can have a different balance of activity at each receptor. Researchers must measure that balance in defined assays. The number of targets alone does not reveal the molecule, its potency or its clinical value.

This is also why the name GLP-3 can be misleading. It looks as though it should mean “the third GLP,” but that is not its accepted meaning in human physiology. In this catalogue context, it points to a triple-pathway research idea. The exact material still requires its own evidence.

07 · Beginner guide

What benefits do people hear about?

Use the surrounding explanation and cited source for the full context.

Online conversations often group several outcomes together: feeling fuller, improved glucose measurements, body-weight reduction and cardiovascular benefits. Those topics do not belong to every product carrying a similar-looking name.

Appetite and fullness

Named GLP-1 and dual GIP/GLP-1 medicines have been studied for their effects on appetite and food intake. The effect must be attributed to the exact medicine, population and study. It cannot be advertised as a benefit of the Emirates GLP-3 Research Pen.

Blood-glucose outcomes

Some named medicines are approved for type 2 diabetes in particular jurisdictions. For example, the January 2026 US Mounjaro prescribing information identifies tirzepatide as a GIP and GLP-1 receptor agonist indicated, alongside diet and exercise, to improve glycaemic control in defined people with type 2 diabetes. That is a statement about Mounjaro under a US label, not a blanket statement about GLP pens in the UAE.

Body-weight outcomes

Semaglutide, tirzepatide and retatrutide have each been studied in their own programmes. They are not the same molecule, and the studies used different populations, comparators, durations and protocols. A percentage reported in one trial is not a prediction for another medicine, and it is certainly not evidence for an unidentified catalogue product.

Cardiovascular and other metabolic outcomes

Some specific products have official indications or published outcome trials covering cardiovascular risk or other metabolic endpoints. The exact product label matters. “GLP medicines may have cardiovascular benefits” is too broad unless the article names the medicine, source, population and endpoint.

The safe way to read a benefit claim is to ask four questions: Which molecule? Which product label or study? Which population? Which jurisdiction?

08 · Beginner guide

Are GLP medicines used for diabetes?

Use the surrounding explanation and cited source for the full context.

Some named GLP-related medicines are used for type 2 diabetes, but not every GLP medicine has the same indication, and a research pen is not part of a treatment decision.

Type 2 diabetes involves problems with glucose regulation, including insulin resistance and changes in insulin secretion. GLP-1 receptor medicines can support glucose-dependent insulin signalling, while tirzepatide combines GIP and GLP-1 receptor activity. Their approved uses, age groups, warnings and contraindications are set out in their own product information.

Type 1 diabetes is a different condition involving autoimmune loss of insulin-producing beta cells. Readers should not assume that information about type 2 diabetes applies to type 1 diabetes.

For a person asking, “Could a GLP medicine be suitable for me?”, the correct route is:

1. Identify the exact approved medicine.
2. Check the current indication in the relevant country.
3. Review the diagnosis, medical history, other medicines and contraindications.
4. Discuss the decision with a licensed clinician.

This article cannot perform that assessment. More importantly, the process above does not turn the Emirates GLP-3 Research Pen into a diabetes product. It remains a research-only catalogue item.

09 · Beginner guide

How long do GLP medicines last?

Use the surrounding explanation and cited source for the full context.

“How long does it last?” sounds like a simple question, but it can refer to at least four different things.

Half-life

Half-life is the time required for the amount of a named drug in the body to fall by roughly half. The 2026 US Wegovy label describes semaglutide as having an elimination half-life of approximately one week. The 2026 US Mounjaro label describes tirzepatide as having a half-life of approximately five days.

Those figures help explain the pharmacokinetics of those named medicines. They do not tell us how a product labelled GLP-3 behaves.

Labelled dosing interval

The schedule on an approved medicine’s label is not the same as its half-life. This article does not reproduce dosing or administration instructions.

Study duration

A clinical trial may follow participants for 40, 48 or 72 weeks. That number tells you how long the study collected data. It does not mean an individual will experience a particular outcome at the same time.

Outcome timeline

Researchers choose specific times to measure changes in glucose, body weight or other endpoints. A result at week 24 and a result at week 48 answer different questions. Study averages also hide variation between participants.

There is therefore no responsible evidence-based answer to “How long does the Emirates GLP-3 Pen work?” The catalogue name and pen format do not establish pharmacokinetics, labelled frequency or clinical duration.

10 · Beginner guide

What has retatrutide research reported?

Use the surrounding explanation and cited source for the full context.

Retatrutide is relevant because it is a named triple agonist. It is not relevant as proof of what is inside every product labelled GLP-3.

In the 2023 phase 2 trial titled Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial, 338 adults were followed for 48 weeks. The study reported changes in body weight across specified retatrutide groups and placebo. Gastrointestinal events were the most common adverse events, and dose-dependent increases in heart rate were observed.

The study tells us about retatrutide in that population, under that protocol. It does not authenticate a catalogue product, prove batch identity or predict what another material will do.

As of July 2026, Lilly continues to describe retatrutide as investigational and not approved by any regulatory agency. Sponsor announcements about Phase 3 programmes may be useful updates, but a press release is not the same as a complete peer-reviewed report.

For readers, the practical rule is simple: if a graph comes from a retatrutide trial, its title, source and warning should all say retatrutide. It should never be captioned as a result of “the GLP-3 Pen.”

11 · Beginner guide

Side effects and warnings

Use the surrounding explanation and cited source for the full context.

Named GLP-1 and GIP/GLP-1 medicines can cause side effects, but the details vary by product and label. Commonly reported effects in major trials and official labels include gastrointestinal symptoms such as nausea, diarrhoea, vomiting, constipation or abdominal discomfort.

Official labels also contain more serious warnings and contraindications. Depending on the exact medicine, these can cover matters such as pancreatitis, gallbladder disease, dehydration-related kidney problems, severe gastrointestinal reactions, hypoglycaemia when combined with certain glucose-lowering medicines, hypersensitivity and specific thyroid-tumour warnings based on rodent findings.

This is not a complete safety list. A person considering an approved medicine needs the current local product information and an individual clinical assessment. Pregnancy, medical history, other medicines and the reason for treatment can materially change that assessment.

A named medicine’s safety information also cannot be used to declare an unidentified material safe. “Similar pathway” does not mean identical composition, manufacturing quality, pharmacokinetics or adverse-effect profile.

12 · Beginner guide

Who can use an approved GLP medicine?

There is no single answer for the whole category. Eligibility depends on the exact medicine and the indication approved in the relevant jurisdiction.

One named product may have an indication for type 2 diabetes. Another may have a weight-management indication for adults meeting specific criteria. A different product may have additional cardiovascular or metabolic indications. The same active ingredient can also appear under different brand names with different labels.

A clinician reviews much more than a person’s interest in weight loss. The assessment can include diagnosis, age, body-mass criteria where relevant, previous treatment, gastrointestinal history, pancreatic or gallbladder history, kidney function, pregnancy considerations, family history, current medicines and the risk of interactions or hypoglycaemia.

This section is about approved medicines. It does not identify anyone who should use the Emirates GLP-3 Research Pen, which is not for personal use.

13 · Beginner guide

Why evidence cannot jump between products

Use the surrounding explanation and cited source for the full context.

Four kinds of evidence often appear together online, even though they answer different questions.

This separation protects readers from a common online shortcut: starting with a result from semaglutide, tirzepatide or retatrutide and ending with a sales claim for a different product.

14 · Beginner guide

The Emirates Peptides GLP-3 Research Pen

Use the surrounding explanation and cited source for the full context.

The Emirates Peptides listing describes a research pen with 20 mg of labelled research material in a 3 ml integrated cartridge format. The product page may also show the external device, inspection area and catalogue presentation.

These are format facts. They do not tell a reader that the pen is a medicine, that it contains retatrutide, that it produces a clinical benefit or that the labelled content represents a human dose.

For qualified laboratory research, useful records can include:

• Exact catalogue name.
• Labelled content and cartridge volume.
• Batch or lot identifier.
• Matching certificate or analytical documentation.
• Receipt date and package condition.
• Storage instruction and temperature record.
• Any expiry or retest information supplied.

Identity, purity, concentration, sterility, stability and biological activity are separate claims. A purity percentage cannot establish all of them. A clean photograph cannot establish any of them.

Readers can view the live GLP-3 Pen 20 mg research listing to check its current catalogue status. Availability can change, so this guide uses Check current availability rather than making a permanent stock promise.

15 · Beginner guide

What should Dubai and Abu Dhabi readers know?

The meaning of GLP-1, tirzepatide or retatrutide does not change between Dubai and Abu Dhabi. The same evidence boundaries apply throughout the UAE.

Location matters mainly for the practical context of the search. A reader may be looking for a basic explanation, trying to compare terms, checking a product format or reviewing laboratory documentation. This page answers those questions without making a claim that a research product is approved for treatment in the UAE.

For a laboratory receiving temperature-sensitive research material, an authorised receiver, suitable monitored storage and prompt inspection are sensible parts of a documented workflow. Product and batch instructions should control the actual process. A general article cannot replace them.

Readers comparing research categories may also find the existing GLP-3 vs semaglutide guide and Cagrilintide vs GLP-3 research comparison useful. Those pages should be read as category comparisons, not personal treatment recommendations.

16 · Beginner guide

Common mistakes to avoid

“GLP-3 must be the next version of GLP-1”

No. GLP-1 is a recognised hormone. GLP-3 is used here as an informal catalogue label associated with triple-receptor research.

“GLP-3 means retatrutide”

No. Retatrutide is a named molecule. The GLP-3 label alone does not establish that identity.

“Three receptors must be better than two”

No. Receptor count does not rank effectiveness or safety. Balance, potency, molecule design, evidence and clinical context all matter.

“A pen means it is an approved medicine”

No. A pen is a container and device format. Approval belongs to the exact product and jurisdiction.

“A 48-week study tells me when I will see a result”

No. Study duration, measurement points and individual response are different things.

“Research-only wording makes clinical claims acceptable”

No. A disclaimer does not turn unsupported treatment or outcome claims into responsible information.

17 · Beginner guide

The simple takeaway

Use the surrounding explanation and cited source for the full context.

GLP-1 is a naturally occurring peptide hormone, and GLP-1 receptor signalling is the biological pathway. Semaglutide is a named GLP-1 receptor medicine. Mounjaro contains tirzepatide, a named dual GIP/GLP-1 receptor medicine. Retatrutide is a named investigational triple agonist.

The Emirates Peptides GLP-3 Research Pen is different: GLP-3 is an informal catalogue label associated with triple-receptor research. The label and pen shape do not establish a named-drug identity, medical use or expected duration.

For treatment questions, use the exact local medicine label and speak with a licensed clinician. For qualified laboratory research, use the exact catalogue record, batch documentation and current product listing.

18 · Beginner guide

Frequently asked questions

Official labels and primary references

1. US Food and Drug Administration. MOUNJARO (tirzepatide) Injection, for subcutaneous use — Prescribing Information. Revised January 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s009lbl.pdf
2. US Food and Drug Administration. WEGOVY (semaglutide) tablets and injection — Prescribing Information. 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf
3. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. New England Journal of Medicine. 2023. PMID: 37366315. DOI: 10.1056/NEJMoa2301972. https://pubmed.ncbi.nlm.nih.gov/37366315/
4. Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021. PMID: 34170647. DOI: 10.1056/NEJMoa2107519. https://pubmed.ncbi.nlm.nih.gov/34170647/
5. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021. PMID: 33567185. DOI: 10.1056/NEJMoa2032183. https://pubmed.ncbi.nlm.nih.gov/33567185/
6. Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism. 2022. PMID: 35985340. DOI: 10.1016/j.cmet.2022.07.013. https://pubmed.ncbi.nlm.nih.gov/35985340/
7. Eli Lilly and Company. What to know about retatrutide. Medically reviewed and updated July 2026. https://www.lilly.com/news/stories/what-to-know-about-retatrutide